Merck Frosst Canada Welcomes Health Canada Scientific Advisory Panel On COX-2 Inhibitors
10/19/2005 5:13:04 PM
MONTREAL, April 18 /CNW/ - Merck Frosst recognizes as an important public health matter, the safety profile of the selective COX-2 inhibitors and NSAID classes. As such, the Company welcomes recent announcements from Health Canada that it will convene a scientific advisory panel to evaluate selective COX-2 inhibitors later this spring.
comments powered by